176 related articles for article (PubMed ID: 29980531)
41. ImmunoPET Imaging of Insulin-Like Growth Factor 1 Receptor in a Subcutaneous Mouse Model of Pancreatic Cancer.
England CG; Kamkaew A; Im HJ; Valdovinos HF; Sun H; Hernandez R; Cho SY; Dunphy EJ; Lee DS; Barnhart TE; Cai W
Mol Pharm; 2016 Jun; 13(6):1958-66. PubMed ID: 27054683
[TBL] [Abstract][Full Text] [Related]
42. The effect of tumor CEA content and tumor size on tissue uptake of indium 111-labeled anti-CEA monoclonal antibody.
Philben VJ; Jakowatz JG; Beatty BG; Vlahos WG; Paxton RJ; Williams LE; Shively JE; Beatty JD
Cancer; 1986 Feb; 57(3):571-6. PubMed ID: 3942992
[TBL] [Abstract][Full Text] [Related]
43. PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody.
Cai W; Olafsen T; Zhang X; Cao Q; Gambhir SS; Williams LE; Wu AM; Chen X
J Nucl Med; 2007 Feb; 48(2):304-10. PubMed ID: 17268029
[TBL] [Abstract][Full Text] [Related]
44. PET/CT Imaging of
Li W; Wang Y; Rubins D; Bennacef I; Holahan M; Haley H; Purcell M; Gantert L; Hseih S; Judo M; Seghezzi W; Zhang S; van der Veen EL; Lub-de Hooge MN; de Vries EGE; Evelhoch JL; Klimas M; Hostetler ED
Mol Imaging Biol; 2021 Apr; 23(2):250-259. PubMed ID: 33104972
[TBL] [Abstract][Full Text] [Related]
45. A mouse/human-chimeric bispecific antibody reactive with human carcinoembryonic antigen-expressing cells and human T-lymphocytes.
Kuwahara M; Kuroki M; Arakawa F; Senba T; Matsuoka Y; Hideshima T; Yamashita Y; Kanda H
Anticancer Res; 1996; 16(5A):2661-7. PubMed ID: 8917366
[TBL] [Abstract][Full Text] [Related]
46. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
[TBL] [Abstract][Full Text] [Related]
47. SPECT- and fluorescence image-guided surgery using a dual-labeled carcinoembryonic antigen-targeting antibody.
Rijpkema M; Oyen WJ; Bos D; Franssen GM; Goldenberg DM; Boerman OC
J Nucl Med; 2014 Sep; 55(9):1519-24. PubMed ID: 24982436
[TBL] [Abstract][Full Text] [Related]
48. Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models.
Liapis V; Tieu W; Wittwer NL; Gargett T; Evdokiou A; Takhar P; Rudd SE; Donnelly PS; Brown MP; Staudacher AH
Mol Imaging Biol; 2021 Dec; 23(6):914-928. PubMed ID: 34231102
[TBL] [Abstract][Full Text] [Related]
49.
Burvenich IJ; Lee FT; Guo N; Gan HK; Rigopoulos A; Parslow AC; O'Keefe GJ; Gong SJ; Tochon-Danguy H; Rudd SE; Donnelly PS; Kotsuma M; Ohtsuka T; Senaldi G; Scott AM
Theranostics; 2016; 6(12):2225-2234. PubMed ID: 27924159
[No Abstract] [Full Text] [Related]
50. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody.
Christensen C; Kristensen LK; Alfsen MZ; Nielsen CH; Kjaer A
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1302-1313. PubMed ID: 31883023
[TBL] [Abstract][Full Text] [Related]
51. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
[TBL] [Abstract][Full Text] [Related]
52. Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives.
Viola-Villegas NT; Sevak KK; Carlin SD; Doran MG; Evans HW; Bartlett DW; Wu AM; Lewis JS
Mol Pharm; 2014 Nov; 11(11):3965-73. PubMed ID: 24779727
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of (89)Zr-labeled human anti-CD147 monoclonal antibody as a positron emission tomography probe in a mouse model of pancreatic cancer.
Sugyo A; Tsuji AB; Sudo H; Nagatsu K; Koizumi M; Ukai Y; Kurosawa G; Zhang MR; Kurosawa Y; Saga T
PLoS One; 2013; 8(4):e61230. PubMed ID: 23577210
[TBL] [Abstract][Full Text] [Related]
54. PET Imaging of Tumor-Associated Macrophages with 89Zr-Labeled High-Density Lipoprotein Nanoparticles.
Pérez-Medina C; Tang J; Abdel-Atti D; Hogstad B; Merad M; Fisher EA; Fayad ZA; Lewis JS; Mulder WJ; Reiner T
J Nucl Med; 2015 Aug; 56(8):1272-7. PubMed ID: 26112022
[TBL] [Abstract][Full Text] [Related]
55. Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas.
Pishvaian M; Morse MA; McDevitt J; Norton JD; Ren S; Robbie GJ; Ryan PC; Soukharev S; Bao H; Denlinger CS
Clin Colorectal Cancer; 2016 Dec; 15(4):345-351. PubMed ID: 27591895
[TBL] [Abstract][Full Text] [Related]
56. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
[TBL] [Abstract][Full Text] [Related]
57. Tumor-Specific Zr-89 Immuno-PET Imaging in a Human Bladder Cancer Model.
Escorcia FE; Steckler JM; Abdel-Atti D; Price EW; Carlin SD; Scholz WW; Lewis JS; Houghton JL
Mol Imaging Biol; 2018 Oct; 20(5):808-815. PubMed ID: 29508263
[TBL] [Abstract][Full Text] [Related]
58. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing
Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA
Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305
[TBL] [Abstract][Full Text] [Related]
59. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
[TBL] [Abstract][Full Text] [Related]
60. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab.
Jagoda EM; Vasalatiy O; Basuli F; Opina ACL; Williams MR; Wong K; Lane KC; Adler S; Ton AT; Szajek LP; Xu B; Butcher D; Edmondson EF; Swenson RE; Greiner J; Gulley J; Eary J; Choyke PL
Mol Imaging; 2019; 18():1536012119829986. PubMed ID: 31044647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
